Aigen Investment Management LP Lowers Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Aigen Investment Management LP trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 81.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,823 shares of the biotechnology company's stock after selling 7,994 shares during the quarter. Aigen Investment Management LP's holdings in Sarepta Therapeutics were worth $228,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Fifth Third Wealth Advisors LLC bought a new position in shares of Sarepta Therapeutics in the 2nd quarter worth about $607,000. Teachers Retirement System of The State of Kentucky purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $4,771,000. Securian Asset Management Inc. bought a new stake in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $1,187,000. Natixis Advisors LLC purchased a new stake in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $1,918,000. Finally, Edgestream Partners L.P. bought a new position in Sarepta Therapeutics during the 1st quarter valued at approximately $627,000. Hedge funds and other institutional investors own 86.68% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on SRPT. Needham & Company LLC reissued a "buy" rating and issued a $205.00 target price on shares of Sarepta Therapeutics in a report on Thursday, November 7th. Piper Sandler cut their price objective on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an "overweight" rating on the stock in a research report on Thursday, August 8th. William Blair raised shares of Sarepta Therapeutics to a "strong-buy" rating in a report on Friday, August 30th. Evercore ISI dropped their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a research note on Thursday, November 7th. Finally, Guggenheim raised their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. One research analyst has rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $181.33.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock traded down $4.57 during mid-day trading on Friday, reaching $104.54. 1,571,012 shares of the company's stock traded hands, compared to its average volume of 996,282. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a market capitalization of $9.99 billion, a PE ratio of 83.63 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 12 month low of $78.67 and a 12 month high of $173.25. The firm has a 50 day moving average price of $123.72 and a two-hundred day moving average price of $132.38.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares of the company's stock, valued at $4,662,822.56. The trade was a 14.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.70% of the stock is owned by company insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.